Frontlight ResearchEarly access
CompletedNo phase
Renal Cell Arrest and Damage Biomarkers in Progression and Outcome of Septic AKI
Key facts
- Who runs it
- Alexandria University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 80 people enrolled
- Started
- 1 Oct 2023
- Ended
- 1 Jun 2024
- Type of study
- Interventional
- Treatments tested
- renal cell arrest and damage biomarkers assessment
- Record updated
- 18 June 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- AKI stage 1 or 2 according to KDIGO definition
- Sepsis is defined based on the third international consensus definitions for sepsis and septic shock (Sepsis-3) as life threatening organ dysfunction caused by a dysregulated host response to infection. At least two of systemic inflammatory response syndrome (SIRS) criteria should be present
Who cannot take part
- Previous renal replacement therapy
- Renal transplant recipients
- Hepatorenal syndrome
- Patients for whom survival to 30 days is unlikely due to end stage disease (end stage liver or heart disease or untreatable malignancy)
- Patients with pre-existing chronic kidney disease (eGFR<60 ml/min/1.73m2)
- Age less than 18 years
- Acute kidney injury caused by permanent postrenal obstruction
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of the current study is to assess the predictive value of renal cell arrest biomarkers (urinary TIMP2 and IGFBP7), renal damage biomarkers (urinary KIM-1) and microscopic examination of urinary sediment in progression and outcome of sepsis associated AKI.
The group in the trial
- septic AKI patientsTreatment being tested
80 patients with sepsis associated AKI stage 1 or 2 according to KDIGO definition
Treatment: renal cell arrest and damage biomarkers assessment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Role of Renal Cell Arrest and Damage Biomarkers in Progression and Outcome of Sepsis Associated AKI
- Publications
- Record updated
- 18 June 2024